Lacrimal Gland Marginal Zone Lymphoma: Regression after Treatment of Chronic Hepatitis C Virus Infection: Case Report and Review of the Literature

Çoşkun, Adil; Yukselen, Ozden; Yukselen, Vahit; Karaoglu, A. Onder

doi:10.2169/internalmedicine.52.0450

Cited by 9 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature search retrieved 743 studies. We then selected 21 studies in our literature search reporting AVT in the setting of HCV‐associated lymphoma. One study had to be excluded because the only case included featured Hodgkin's lymphoma .…”

Section: Resultsmentioning

confidence: 99%

The anti‐lymphoma activity of antiviral therapy in HCV‐associated B‐cell non‐Hodgkin lymphomas: a meta‐analysis

Peveling‐Oberhag

Arcaini

Bankov

et al. 2016

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Many epidemiological studies provide solid evidence for an association of chronic hepatitis C virus (HCV) infection with B-cell non-Hodgkin's lymphoma (B-NHL). However, the most convincing evidence for a causal relationship between HCV infection and lymphoma development is the observation of B-NHL regression after HCV eradication by antiviral therapy (AVT). We conducted a literature search to identify studies that included patients with HCV-associated B-NHL (HCV-NHL) who received AVT, with the intention to treat lymphoma and viral disease at the same time. The primary end point was the correlation of sustained virological response (SVR) under AVT with lymphoma response. Secondary end points were overall lymphoma response rates and HCV-NHL response in correlation with lymphoma subtypes. We included 20 studies that evaluated the efficacy of AVT in HCV-NHL (n = 254 patients). Overall lymphoma response rate through AVT was 73% [95%>confidence interval, (CI) 67-78%]. Throughout studies there was a strong association between SVR and lymphoma response (83% response rate, 95%>CI, 76-88%) compared to a failure in achieving SVR (53% response rate, 95%>CI, 39-67%, P = 0.0002). There was a trend towards favourable response for AVT in HCV-associated marginal zone lymphomas (response rate 81%, 95%>CI, 74-87%) compared to nonmarginal zone origin (response rate 71%, 95%>CI, 61-79%, P = 0.07). In conclusion, in the current meta-analysis, the overall response rate of HCV-NHL under AVT justifies the recommendation for AVT as first-line treatment in patients who do not need immediate conventional treatment. The strong correlation of SVR and lymphoma regression supports the hypothesis of a causal relationship of HCV and lymphomagenesis.

show abstract

Section: Resultsmentioning

confidence: 99%

The anti‐lymphoma activity of antiviral therapy in HCV‐associated B‐cell non‐Hodgkin lymphomas: a meta‐analysis

Peveling‐Oberhag

Arcaini

Bankov

et al. 2016

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…66,[108][109][110] A rare clinical presentation has been described, namely the subcutaneous "lipoma-like" MALT lymphoma. This condition typically affects elderly women and exhibits single or multiple soft and mobile subcutaneous nodules that may regress after HCV eradication.…”

Section: Hcv and Malt Lymphomasmentioning

confidence: 99%

The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance

Zucca

Bertoni

2016

Blood

235

205

View full text Add to dashboard Cite

Extranodal marginal zone (MZ) B-cell lymphomas of the mucosa-associated lymphoid tissue (MALT) arise from lymphoid populations that are induced by chronic inflammation in extranodal sites. The best evidence of an etiopathogenetic link is provided by the association between Helicobacter pylori–positive gastritis and gastric MALT lymphoma. Indeed, successful eradication of this microorganism with antibiotics can be followed by gastric MALT lymphoma regression in most cases. Other microbial agents have been implicated in the pathogenesis of MZ lymphoma arising at different sites. Apart from gastric MALT lymphoma, antibiotic therapies have been adequately tested only in ocular adnexal MALT lymphomas where upfront doxycycline may be a reasonable and effective initial treatment of patients with Chlamydophila psittaci–positive lymphoma before considering more aggressive strategies. In all other instances, antibiotic treatment of nongastric lymphomas remains investigational. Indeed, there is no clear consensus for the treatment of patients with gastric MALT lymphoma requiring further treatment beyond H pylori eradication or with extensive disease. Both radiotherapy and systemic treatments with chemotherapy and anti-CD20 antibodies are efficacious and thus the experience of individual centers and each patient’s preferences in terms of adverse effects are important parameters in the decision process.

show abstract

“…The association between non-Hodgkin lymphoma and the HCV is described in previous studies (59,60) . Some ocular and orbital tumors, such as lacrimal gland lymphoma (61) and rare tumors such as orbital plasmacytoma, are reported to be associated with the HCV (62) . Extranodal marginal zone lymphoma of MALT-type (MALT lymphoma), the subtype found most commonly in ocular adnexal lymphoma, is also associated with HCV infection (63) .…”

Section: Hcv and Its Associations With Tumors Of The Eye And Its Adnexamentioning

confidence: 99%

O olho na hepatite C: uma revisão

Bertrand

Gomes

et al. 2019

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

| This review aims to caution ophthalmologists about the ocular consequences leading to the diagnosis of hepatitis C virus infection. In addition, in this context, the effects of old and new drugs are discussed in the ophthalmological setting. The importance of early diagnosis and the curative treatment of the disease has been reported in the national and international literature, demonstrating that its progression has important implications for daily clinical and surgical ophthalmological practice. Despite the scarcity of studies on new direct-acting antiviral drugs, fewer side effects of these drugs have been shown when compared with conventional interferon treatment with or without ribavirin. The ophthalmologist's risk of becoming infected, as demonstrated by the presence of the virus in ocular structures, and the possibility of contamination, is also discussed.Keywords: Hepatitis C/ complications; Hepatitis C/drug therapy; Interferon/therapeutic use; Direct-acting antiviral drugs RESUMO | Esta revisão objetiva alertar os oftalmologistas sobre as consequências oculares que levam ao diagnóstico da infecção pelo vírus da Hepatite C. Além disso, neste contexto, os efeitos de drogas antigas e novas são discutidos no cenário oftalmológico. A importância do diagnóstico precoce e do tratamento curativo da doença tem sido relatada na literatura nacional e internacional, demonstrando que sua progressão tem implicações importantes para a prática oftalmológica diária. Apesar da escassez de estudos sobre novos medicamentos antivirais de ação direta, foram demonstrados menos efeitos colaterais desses medicamentos quando comparados ao tratamento convencional com interferon, com ou sem ribavirina associado ou não à rivabirina. O risco do oftalmologista de se infectar, como demonstrado pela presença do vírus nas estruturas oculares, e a possibilidade de contaminação, também é discutido.Descritores: Hepatite C/complicações; Hepatite C/tratamento farmacológico; Interferon/uso terapêutico; Drogas antivirais de ação direta

show abstract

Lacrimal Gland Marginal Zone Lymphoma: Regression after Treatment of Chronic Hepatitis C Virus Infection: Case Report and Review of the Literature

Cited by 9 publications

References 30 publications

The anti‐lymphoma activity of antiviral therapy in HCV‐associated B‐cell non‐Hodgkin lymphomas: a meta‐analysis

The anti‐lymphoma activity of antiviral therapy in HCV‐associated B‐cell non‐Hodgkin lymphomas: a meta‐analysis

The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance

O olho na hepatite C: uma revisão

Contact Info

Product

Resources

About